drugset / Trial / NCT02463643

To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis

NCT02463643

Phase 2 Completed 503 enrolled Zeria Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium 10mg in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.

Timeline

Start
2015-05
Primary completion
2016-10
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AZELOPRAZOLE Small molecule 10 mg
Subject AZELOPRAZOLE Small molecule 20 mg
Subject AZELOPRAZOLE Small molecule 40 mg
Comparator Rabeprazole Small molecule 10 mg